Gantenerumab

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials 3:49
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Philip Tipton • 27 Apr 2023
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials 2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway • 19 Apr 2023
Safety results of the Phase III gantenerumab GRADUATE I and II studies 1:50
Safety results of the Phase III gantenerumab GRADUATE I and II studies
Stephen Salloway • 19 Apr 2023
Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310 4:51
Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310
Johanne Kaplan • 30 Mar 2023
Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab 1:23
Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab
Stephen Salloway • 19 Aug 2022
Important developments in dementia: biomarkers & clinical trials 4:52
Important developments in dementia: biomarkers & clinical trials
Philip Tipton • 3 Apr 2022
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab 4:01
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab
Lars Lannfelt • 16 Mar 2022
Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab 1:32
Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab
Stephen Salloway • 13 Aug 2021
The content of VJDementia is intended for healthcare professionals